Sanofi Canada has announced a new option for emergency treatment of anaphylaxis, a dangerous allergic reaction.

Allerject™ is the first and only “talking” epinephrine auto-injector to be introduced in Canada. It is estimated that about 2.5 million Canadians (or 7 percent of the population) have a food allergy.

Epinephrine is the drug used to treat severe allergic reactions.

“Anaphylaxis is potentially life-threatening for many thousands of Canadians, and for these individuals, the prompt and correct use of an epinephrine auto-injector is essential in an allergic emergency,” notes Dr. Amin Kanani, a Vancouver allergist.

Despite the necessity of carrying an epinephrine auto-injector, many patients do not know how to use it correctly. In studies, only 30-44 percent of those with severe allergies were able to demonstrate how to use an auto-injector correctly in order to self-administer a shot of epinephrine.

To help ensure that patients are able to get the medication they need, Allerject™ “talks” the patient through the injection process with automated voice instructions in either English or French. The device has also been redesigned to be easier to carry in a pocket or small purse.

“Allerject™ is designed to address unmet patient needs and make a positive difference in the lives of those at risk of a severe allergic reaction, and those who care for them,” commented CEO and president of Sanofi Canada Jon Fairest.

Invented by Brothers with Food Allergies

The inventors of the new device are Evan and Eric Edwards, twin brothers who both have severe food allergies.

“We’re patients too, and we wanted an auto-injector that would address gaps in the care of individuals at risk of anaphylaxis,” explains Eric.

Their product is designed to help patients get the medication they need during an anaphylactic reaction.

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}